)
Visual
test
Marker Therapeutics
Marker Therapeutics (MRKR) investor relations material
Marker Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Focused on developing non-genetically engineered T cell immunotherapies for hematological malignancies and solid tumors, with lead programs in lymphoma and pancreatic cancer.
Phase 1 APOLLO study for MT-601 in lymphoma showed a 66% objective response rate and 50% complete response rate in relapsed NHL, with durable responses and favorable safety profile.
Manufacturing partnerships expanded, including a cGMP collaboration with Cellipont Bioservices for MT-601 scale-up.
First patient treated in the Off-the-Shelf (OTS) RAPID study for AML/MDS, with encouraging preliminary safety data and non-dilutive funding support.
Raised $10 million through ATM facility, extending cash runway into 2026.
Financial highlights
Grant income was $1.2M for Q3 2025, down 36% year-over-year; $2.4M for the nine months, down 44% year-over-year.
Cash, cash equivalents, and restricted cash totaled $18.9M as of September 30, 2025.
R&D expenses decreased to $2.3M from $3.5M YoY for the quarter; G&A expenses were $1M, up from $0.9M YoY.
Net loss for Q3 2025 was $2.0M (improved from $2.3M YoY); for the nine months, $10.5M (worsened from $6.9M YoY).
Net loss per share for Q3 2025: $(0.12); for nine months: $(0.75).
Outlook and guidance
Current cash position expected to fund operations through Q3 2026, assuming no additional grant funds.
Additional clinical data from APOLLO study and MT-601 pancreatic cancer program launch anticipated in the first half of 2026.
Management is seeking additional capital and grant funding to extend runway beyond Q3 2026.
Anticipates continued net losses as R&D and clinical activities expand.
Elaborate on MT-601 durability's trial impact
OTS program's long-term strategic value
How to extend cash runway beyond Q3 2026?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- APAM
AUM hit $180B, strong returns and Grandview deal drove growth despite equity outflows. - GM
Disciplined transformation, resilient supply chains, and strategic EV focus drive robust results. - BTBT
Transitioned to a strategic asset model with major stakes in Ethereum and AI infrastructure. - PSX
Q4 2025 earnings hit $2.9B, with record refining yields and strong portfolio transformation. - ARCC
FY 2025 delivered $2.01 Core EPS, $1.86 net income/share, and a $0.48 Q1 2026 dividend. - HMN
Record core earnings, 12.4% ROE, and 10% EPS growth guidance for 2026. - AFG
Record underwriting profit, strong ROE, and over $700M returned to shareholders in 2025. - OXBR
Tokenized reinsurance contracts on Solana open Florida's market to global investors. - PNDORA
2025 organic growth reached 6%, with EBIT margin at 23.9% and cautious 2026 outlook. - PRU
Earnings rose 12% to $6.6B; Japan sales pause to cut 2026 earnings by $300M-$350M.
Next Marker Therapeutics earnings date
Q4 202531 Mar, 2026
Marker Therapeutics
Next Marker Therapeutics earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Marker Therapeutics Inc is a U.S.-based biotechnology company focused on the development of immunotherapies for cancer. The company’s therapeutic approach involves multi-tumor antigen-specific T cell therapies that are designed to target various hematological and solid tumors. It conducts clinical trials and research collaborations to advance its cell therapy platforms. It is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage